Skip to main content
SpringerLink
Log in
Book cover

Cancer Survivorship pp 90–100Cite as

Medical and Psychosocial Issues in Hodgkin’s Disease Survivors

  • Chapter

Abstract

The first attempts to treat Hodgkin’s disease by radiotherapy were conducted at the beginning of the last century. The prognosis for survival was poor but slowly improved by the use of radiotherapy and some chemotherapy until 1960. For example, in 1939 a 20-year survival rate of 17% was reported.1

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   79.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Gilbert R. Radiotherapy in Hodgkin’s disease (malignant granulomatosis): anatomic and clinical foundations, governing principles, results. Am J Roentgenol 1939;41:198–241.

    Google Scholar 

  2. De Vita VT, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med 1970;73:881–895.

    Google Scholar 

  3. Easson EC, Russel MH. The cure of Hodgkin’s disease. Br Med J 1963;1:1704–1707.

    PubMed  Google Scholar 

  4. Easson EC. Possibilities for the cure of Hodgkin’s disease. Cancer (Phila) 1966;19:345–350.

    Article  Google Scholar 

  5. Wessely S, Hotopf M, Sharpe M. Chronic fatigue and its syndromes. Oxford: Oxford University Press, 1999.

    Google Scholar 

  6. Foss AA, Egeland T, Hansen S, Langholm R, Holte H, Kvaloy S. Hodgkin’s disease in a national and hospital population: trends over 20 years. Eur J Cancer 1997;33(14):2380–2383.

    Article  Google Scholar 

  7. Thomas RK, Re D, Zander T, Wolf J, Diehl V. Epidemiology and etiology of Hodgkin’s lymphoma. Ann Oncol 2002;13(suppl 4):147–152.

    PubMed  Google Scholar 

  8. Glaser SL, Swartz WG. Time trends in Hodgkin’s disease incidence. The role of diagnostic accuracy. Cancer (Phila) 1990;66(10):2196–2204.

    Article  CAS  Google Scholar 

  9. Glaser SL. Recent incidence and secular trends in Hodgkin’s disease and its histologic subtypes. J Chronic Dis 1986;39(10):789–798.

    Article  PubMed  CAS  Google Scholar 

  10. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van’t Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol 2003;21(18):3431–3439.

    Article  PubMed  Google Scholar 

  11. Vaughan HB, Vaughan HG, Linch DC, Anderson L. Late mortality in young BNLI patients cured of Hodgkin’s disease. Ann Oncol 1994;5(suppl 2)0:65–66.

    Google Scholar 

  12. The Cancer Registry of Norway. Cancer in Norway 2001. Oslo: The Cancer Registry of Norway, 2004.

    Google Scholar 

  13. The Cancer Registry of Norway. Cancer in Norway 1992. Oslo: The Cancer Registry of Norway, 1992.

    Google Scholar 

  14. Canellos GP. Primary treatment of Hodgkin’s disease. Ann Oncol 2002;13(suppl 4):153–158.

    PubMed  Google Scholar 

  15. Josting A, Engert A, Diehl V, Canellos GP. Prognostic factors and treatment outcome in patients with primary progressive and relapsed Hodgkin’s disease. Ann Oncol 2002;13(suppl 1):112–116.

    PubMed  Google Scholar 

  16. Donaldson SS, Hancock SL, Hoppe RT. The Janeway lecture. Hodgkin’s disease: finding the balance between cure and late effects. Cancer J Sci Am 1999;5(6):325–333.

    PubMed  CAS  Google Scholar 

  17. Yung L, Linch D. Hodgkin’s lymphoma. Lancet 2003;361(9361):943–951.

    Article  PubMed  Google Scholar 

  18. Ng AK, Bernardo MP, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin’s disease treated at age 50 or younger. J Clin Oncol 2002;20(8):2101–2108.

    Article  PubMed  Google Scholar 

  19. van Rijswijk RE, Verbeek J, Haanen C, Dekker AW, van Daal WA, van Peperzeel HA. Major complications and causes of death in patients treated for Hodgkin’s disease. J Clin Oncol 1987;5(10):1624–1633.

    PubMed  Google Scholar 

  20. Abrahamsen AF, Loge JH, Hannisdal E, et al. Late medical sequelae after therapy for supradiaphragmatic Hodgkin’s disease. Acta Oncol 1999;38(4):511–515.

    Article  PubMed  CAS  Google Scholar 

  21. Boivin JF, Hutchison GB, Lubin JH, Mauch P. Coronary artery disease mortality in patients treated for Hodgkin’s disease. Cancer (Phila) 1992;69(5):1241–1247.

    Article  PubMed  CAS  Google Scholar 

  22. Cosset JM, Henry-Amar M, Pellae-Cosset B, et al. Pericarditis and myocardial infarctions after Hodgkin’s disease therapy. Int J Radiat Oncol Biol Phys 1991;21(2):447–449.

    PubMed  CAS  Google Scholar 

  23. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA 1993;270(16):1949–1955.

    Article  PubMed  CAS  Google Scholar 

  24. Sears JD, Greven KM, Ferree CR, D’Agostino RB Jr. Definitive irradiation in the treatment of Hodgkin’s disease. Analysis of outcome, prognostic factors, and long-term complications. Cancer (Phila) 1997;79(1):145–151.

    Article  PubMed  CAS  Google Scholar 

  25. Lund MB, Ihlen H, Voss BM, et al. Increased risk of heart valve regurgitation after mediastinal radiation for Hodgkin’s disease: an echocardiographic study. Heart 1996;75(6):591–595.

    PubMed  CAS  Google Scholar 

  26. Gustavsson A, Eskilsson J, Landberg T, et al. Late cardiac effects after mantle radiotherapy in patients with Hodgkin’s disease. Ann Oncol 1990;1(5):355–363.

    PubMed  CAS  Google Scholar 

  27. Glanzmann C, Huguenin P, Lutolf UM, Maire R, Jenni R, Gumppenberg V. Cardiac lesions after mediastinal irradiation for Hodgkin’s disease. Radiother Oncol 1994;30(1):43–54.

    Article  PubMed  CAS  Google Scholar 

  28. Hancock SL, Cox RS, McDougall IR. Thyroid diseases after treatment of Hodgkin’s disease. N Engl J Med 1991;325(9):599–605.

    Article  PubMed  CAS  Google Scholar 

  29. Peerboom PF, Hassink EA, Melkert R, DeWit L, Nooijen WJ, Bruning PF. Thyroid function 10-18 years after mantle field irradiation for Hodgkin’s disease. Eur J Cancer 1992;28A(10):1716–1718.

    Article  PubMed  CAS  Google Scholar 

  30. Brierley JD, Rathmell AJ, Gospodarowicz MK, et al. Late effects of treatment for early-stage Hodgkin’s disease. Br J Cancer 1998;77(8):1300–1310.

    PubMed  CAS  Google Scholar 

  31. Bethge W, Guggenberger D, Bamberg M, Kanz L, Bokemeyer C. Thyroid toxicity of treatment for Hodgkin’s disease. Ann Hematol 2000;79(3):114–118.

    Article  PubMed  CAS  Google Scholar 

  32. Mauch P, Tarbell N, Weinstein H, et al. Stage IA and IIA supradiaphragmatic Hodgkin’s disease: prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation. J Clin Oncol 1988;6(10):1576–1583.

    PubMed  CAS  Google Scholar 

  33. Hassink EA, Souren TS, Boersma LJ, et al. Pulmonary morbidity 10–18 years after irradiation for Hodgkin’s disease. Eur J Cancer 1993;29A(3):343–347.

    Article  PubMed  CAS  Google Scholar 

  34. Loyer E, Fuller L, Libshitz HI, Palmer JL. Radiographic appearance of the chest following therapy for Hodgkin disease. Eur J Radiol 2000;35(2):136–148.

    Article  PubMed  CAS  Google Scholar 

  35. Lund MB, Kongerud J, Nome O, et al. Lung function impairment in long-term survivors of Hodgkin’s disease. Ann Oncol 1995;6(5):495–501.

    PubMed  CAS  Google Scholar 

  36. Koocher G, O’Malley J. The Damocles Syndrome: Psychosocial Consequences of Surviving Childhood Cancer. New York: McGraw-Hill, 1981.

    Google Scholar 

  37. Tross S, Holland JC. Psychological sequelae in cancer survivors. In: Holland JC, Rowland JH (eds). Handbook of Psychooncology. London: Oxford University Press, 1990:101–116.

    Google Scholar 

  38. Cella DF, Tross S. Psychological adjustment to survival from Hodgkin’s disease. J Consult Clin Psychol 1986;54(5):616–622.

    Article  PubMed  CAS  Google Scholar 

  39. The Constitution of the World Health Organisation. WHO Chronicle 1947;29.

    Google Scholar 

  40. Fobair P, Hoppe RT, Bloom J, Cox R, Varghese A, Spiegel D. Psychosocial problems among survivors of Hodgkin’s disease. J Clin Oncol 1986;4(5):805–814.

    PubMed  CAS  Google Scholar 

  41. Kornblith AB, Anderson J, Cella DF, et al. Hodgkin disease survivors at increased risk for problems in psychosocial adaptation. The Cancer and Leukemia Group B. Cancer (Phila) 1992;70(8):2214–2224.

    Article  PubMed  CAS  Google Scholar 

  42. van Tulder MW, Aaronson NK, Bruning PF. The quality of life of long-term survivors of Hodgkin’s disease. Ann Oncol 1994;5(2):153–158.

    PubMed  Google Scholar 

  43. Norum J, Wist EA. Quality of life in survivors of Hodgkin’s disease. Qual Life Res 1996;5(3):367–374.

    Article  PubMed  CAS  Google Scholar 

  44. Joly F, Henry-Amar M, Arveux P, et al. Late psychosocial sequelae in Hodgkin’s disease survivors: a French populationbased case-control study. J Clin Oncol 1996;14(9):2444–2453.

    PubMed  CAS  Google Scholar 

  45. Aaronson NK, Cull A, Kaasa S. The EORTC modular approach to quality of life assessment in oncology. Int J Ment Health 1994;23:75–96.

    Google Scholar 

  46. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993;11(3):570–579.

    PubMed  CAS  Google Scholar 

  47. Ware JE. The SF-36 health survey. In: Spilker B (ed). Quality of Life and Pharmaeconomics in Clinical Trials. Philadelphia: Lippincott-Raven, 1996:337–346.

    Google Scholar 

  48. Loge JH, Kaasa S. Short form 36 (SF-36) health survey: normative data from the general Norwegian population. Scand J Soc Med 1998;26(4):250–258.

    PubMed  CAS  Google Scholar 

  49. Loge JH, Abrahamsen AF, Ekeberg O, Kaasa S. Reduced health-related quality of life among Hodgkin’s disease survivors: a comparative study with general population norms. Ann Oncol 1999;10(1):71–77.

    Article  PubMed  CAS  Google Scholar 

  50. Bloom JR, Gorsky RD, Fobair P, et al. Physical performance at work and at leisure: validation of a measure of biological energy in survivors of Hodgkin’s disease. J Psychosocial Oncol 1990;8(1):49–63.

    Article  Google Scholar 

  51. Bloom JR, Fobair P, Gritz E, et al. Psychosocial outcomes of cancer: a comparative analysis of Hodgkin’s disease and testicular cancer. J Clin Oncol 1993;11(5):979–988.

    PubMed  CAS  Google Scholar 

  52. Greil R, Holzner B, Kemmler G, et al. Retrospective assessment of quality of life and treatment outcome in patients with Hodgkin’s disease from 1969 to 1994. Eur J Cancer 1999;35(5):698–706.

    Article  PubMed  CAS  Google Scholar 

  53. Olweny CL, Juttner CA, Rofe P, et al. Long-term effects of cancer treatment and consequences of cure: cancer survivors enjoy quality of life similar to their neighbours. Eur J Cancer 1993;29A(6):826–830.

    Article  PubMed  CAS  Google Scholar 

  54. Gil-Fernandez J, Ramos C, Tamayo T, et al. Quality of life and psychological well-being in Spanish long-term survivors of Hodgkin’s disease: results of a controlled pilot study. Ann Hematol 2003;82(1):14–18.

    PubMed  CAS  Google Scholar 

  55. Knobel H, Havard LJ, Brit LM, Forfang K, Nome O, Kaasa S. Late medical complications and fatigue in Hodgkin’s disease survivors. J Clin Oncol 2001;19(13):3226–3233.

    PubMed  CAS  Google Scholar 

  56. Cameron CL, Cella D, Herndon JE, et al. Persistent symptoms among survivors of Hodgkin’s disease: an explanatory model based on classical conditioning. Health Psychol 2001;20(1):71–75.

    Article  PubMed  CAS  Google Scholar 

  57. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998;16(1):139–144.

    PubMed  CAS  Google Scholar 

  58. Lee JQ, Simmonds MJ, Wang XS, Novy DM. Differences in physical performance between men and women with and without lymphoma. Arch Phys Med Rehabil 2003;84(12):1747–1752.

    Article  PubMed  Google Scholar 

  59. Devlen J, Maguire P, Phillips P, Crowther D. Psychological problems associated with diagnosis and treatment of lymphomas. II: Prospective study. Br Med J (Clin Res Ed) 1987;295(6604):955–957.

    CAS  Google Scholar 

  60. Devlen J, Maguire P, Phillips P, Crowther D, Chambers H. Psychological problems associated with diagnosis and treatment of lymphomas. I: Retrospective study. Br Med J (Clin Res Ed) 1987;295(6604):953–954.

    Article  CAS  Google Scholar 

  61. Lewis G, Wessely S. The epidemiology of fatigue: more questions than answers. J Epidemiol Community Health 1992;46(2):92–97.

    PubMed  CAS  Google Scholar 

  62. Pawlikowska T, Chalder T, Hirsch SR, Wallace P, Wright DJ, Wessely SC. Population based study of fatigue and psychological distress [see comments]. BMJ 1994;308(6931):763–766.

    PubMed  CAS  Google Scholar 

  63. Ganz PA, Moinpour CM, Pauler DK, et al. Health status and quality of life in patients with early-stage Hodgkin’s disease treated on Southwest Oncology Group Study 9133. J Clin Oncol 2003;21(18):3512–3519.

    Article  PubMed  Google Scholar 

  64. Kornblith AB, Herndon JE, Zuckerman E, et al. Comparison of psychosocial adaptation of advanced stage Hodgkin’s disease and acute leukemia survivors. Cancer and Leukemia Group B. Ann Oncol 1998;9(3):297–306.

    Article  PubMed  CAS  Google Scholar 

  65. Loge JH, Abrahamsen AF, Ekeberg O, Kaasa S. Hodgkin’s disease survivors more fatigued than the general population. J Clin Oncol 1999;17(1):253–261.

    PubMed  CAS  Google Scholar 

  66. Ruffer JU, Flechtner H, Tralls P, et al. Fatigue in long-term survivors of Hodgkin’s lymphoma: a report from the German Hodgkin Lymphoma Study Group (GHSG). Eur J Cancer 2003;39(15):2179–2186.

    Article  PubMed  CAS  Google Scholar 

  67. Wettergren L, Bjorkholm M, Axdorph U, Bowling A, Langius-Eklof A. Individual quality of life in long-term survivors of Hodgkin’s lymphoma: a comparative study. Qual Life Res 2003;12(5):545–554.

    Article  PubMed  CAS  Google Scholar 

  68. Fossa SD, Dahl AA, Loge JH. Fatigue, anxiety and depression and mental health in long-term survivors of testicular cancer. J Clin Oncol 2003;21:1249–1254.

    Article  PubMed  Google Scholar 

  69. Loge JH, Abrahamsen AF, Ekeberg, Kaasa S. Fatigue and psychiatric morbidity among Hodgkin’s disease survivors. J Pain Symptom Manag 2000;19(2):91–99.

    Article  CAS  Google Scholar 

  70. Visser MR, Smets EM. Fatigue, depression and quality of life in cancer patients: how are they related? Support Care Cancer 1998;6(2):101–108.

    Article  PubMed  CAS  Google Scholar 

  71. Cleeland CS, Bennett GJ, Dantzer R, et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer (Phila) 2003;97(11):2919–2925.

    Article  Google Scholar 

  72. Knobel H, Loge JH, Nordoy T, et al. High level of fatigue in lymphoma patients treated with high dose therapy. J Pain Symptom Manag 2000;19(6):446–456.

    Article  CAS  Google Scholar 

  73. Wessely S, Chalder T, Hirsch S, Wallace P, Wright D. Psychological symptoms, somatic symptoms, and psychiatric disorder in chronic fatigue and chronic fatigue syndrome: a prospective study in the primary care setting. Am J Psychiatry 1996;153(8):1050–1059.

    PubMed  CAS  Google Scholar 

  74. Loge JH, Abrahamsen AF, Ekeberg O, Hannisdal E, Kaasa S. Psychological distress after cancer cure: a survey of 459 Hodgkin’s disease survivors. Br J Cancer 1997;76(6):791–796.

    PubMed  CAS  Google Scholar 

  75. Herrmann C. International experiences with the Hospital Anxiety and Depression Scale: a review of validation data and clinical results. J Psychosom Res 1997;42(1):17–41.

    Article  PubMed  CAS  Google Scholar 

  76. Minaire P. Disease, illness and health: theoretical models of the disablement process. Bull WHO 1992;70(3):373–379.

    PubMed  CAS  Google Scholar 

  77. Abrahamsen AF, Loge JH, Hannisdal E, Holte H, Kvaloy S. Sociomedical situation for long-term survivors of Hodgkin’s disease: a survey of 459 patients treated at one institution. Eur J Cancer 1998;34(12):1865–1870.

    Article  PubMed  CAS  Google Scholar 

  78. Ringdal GI, Ringdal K, Jordhoy MS, Ahlner-Elmqvist M, Jannert M, Kaasa S. Health-related quality of life (HRQOL) in family members of cancer victims: results from a longitudinal intervention study in Norway and Sweden. Palliat Med 2004;18(2):108–120.

    Article  PubMed  Google Scholar 

  79. Oldervoll LM, Kaasa S, Knobel H, Loge JH. Exercise reduces fatigue in chronic fatigued Hodgkin’s disease survivors: results from a pilot study. Eur J Cancer 2003;39(1):57–63.

    Article  PubMed  CAS  Google Scholar 

  80. Whiting P, Bagnall AM, Sowden AJ, Cornell JE, Mulrow CD, Ramirez G. Interventions for the treatment and management of chronic fatigue syndrome: a systematic review. JAMA 2001;286(11):1360–1368.

    Article  PubMed  CAS  Google Scholar 

  81. Morrow GR, Hickok JT, Roscoe JA, et al. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center community clinical oncology program. J Clin Oncol 2003;21(24):4635–4641.

    Article  PubMed  CAS  Google Scholar 

  82. Yehuda R. Post-traumatic stress disorder. N Engl J Med 2002;346(2):108–114.

    Article  PubMed  CAS  Google Scholar 

  83. Gill D, Hatcher S. Antidepressants for depression in people with physical illness. Cochrane Database Syst Rev 2000;2:CD001312.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Behavioral Sciences in Medicine, University of Oslo, Oslo

    Jon Håvard Loge M.D., Ph.D. (Professor)

  2. Centre for Palliative Medicine, Ulleval University Hospital, Oslo, Norway

    Jon Håvard Loge M.D., Ph.D. (Professor)

  3. Department of Cancer Research and Molecular Medicine, Faculty of Medicine, The Norwegian University of Science and Technology, Norway

    Stein Kaasa M.D., Ph.D. (Professor)

  4. Palliative Care Unit, St. Olavs Hospital, Trondheim, Norway

    Stein Kaasa M.D., Ph.D. (Professor)

Authors
  1. Jon Håvard Loge M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stein Kaasa M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Cancer Prevention and Control Research Jonsson Comprehensive Cancer Center, UCLA Schools of Public Health and Medicine, Los Angeles, CA, 90095-6900, USA

    Patricia A. Ganz M.D. (American Cancer Society Research Professor) (American Cancer Society Research Professor)

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Loge, J.H., Kaasa, S. (2007). Medical and Psychosocial Issues in Hodgkin’s Disease Survivors. In: Ganz, P.A. (eds) Cancer Survivorship. Springer, New York, NY. https://doi.org/10.1007/978-0-387-68265-5_8

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-68265-5_8

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-34349-5

  • Online ISBN: 978-0-387-68265-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation